2026/02/24 by Maria Zschummel, Mario Bunse, Anna-Lena Spierling +9 · 1 voice
Immunology and Microbiology · Medicine · #B cell #C-C chemokine receptor type 7 #CAR-T cell therapy research #Chemokine #Chemokine receptor #Chimeric antigen receptor #Cutaneous lymphoproliferative disorders research #Cytokine #Homing (biology) #Immunotherapy and Immune Responses #Lymphoma #NODAL
paper · doi:10.1158/2326-6066.cir-25-1381
openalex publication_date 2026/02/24 · openalex created_date 2026/02/25 · openalex updated_date 2026/08/06
Anti-CD19 chimeric antigen receptor (CAR) therapy demonstrated remarkable efficacy against hematologic malignancies. However, B-cell malignancies with lymph node (LN) involvement frequently remain resistant. In this study, we show that CAR T cells downregulated the chemokine receptor CCR7, crucial for nodal homing, during manufacturing. Consequently, in vitro migration toward the respective chemokines and in vivo migration to LNs was severely impaired. To improve nodal CAR T-cell trafficking, we engineered anti-CXCR5 CAR T cells, targeting mature lymphoma, with stable CCR7 expression (CAR.CCR7). CCR7 engineering of human and mouse CAR T cells restored migratory capacity and LN homing. Additionally, we observed enhanced CAR-mediated killing in CCR7-engineered anti-CXCR5 and anti-CD19 CARs alike, a process that was independent of increased cytokine secretion. Mechanistically, CCR7 overexpression was associated with an altered expression of genes involved in cytoskeletal rearrangement and faster killing kinetics. CCR7 accumulated in mature CAR synapses, supporting the costimulatory role of CCR7 within immunologic synapses. Therapeutically, improved LN recruitment and enhanced killing of CAR.CCR7 T cells improved lymphoma eradication in mice.